Haemodynamic effects of gallopamil in patients with coronary heart disease and/or pulmonary hypertension

  • P. Richter
  • M. Stauch
Conference paper


Calcium antagonists are of proven use for the treatment of coronary heart disease. As is evident from published reports on nifedipine and verapamil (2, 3, 5), like other vasodilators they are also used for the treatment of pulmonary hypertension. Gallopamil, a calcium antagonist of the verapamil type, is a potent vasodilator and caution is required when administering this drug intravenously because its effect on the systemic circulation may result in a fall of blood pressure, and because it has a marked effect on bioelectrical conduction.


Cardiac Output Pulmonary Hypertension Calcium Antagonist Patent Ductus Arteriosus Pulmonary Vascular Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF (1972) Patterns of cardiovascular dysfunction in chronic obstructive lung disease. New Engl J Med Apr: 912–917Google Scholar
  2. 2.
    Henrichs KJ, Erbel R, Meyer J (1985) Wirkung von parenteraler Nifedipingabe bei pulmonaler Hypertonie. In: Meyer, Erbel (eds) Intravenose und intrakoronare Anwendung von Adalat. Springer, Berlin Heidelberg New York Tokyo, pp. 73–79CrossRefGoogle Scholar
  3. 3.
    cLandmark K, Refsum AM, Simonsen S, Storstein O (1978) Verapamil and pulmonary hypertension. Acta Med Scand 204: 299–302PubMedCrossRefGoogle Scholar
  4. 4.
    Packer M, Medina N, Yushak M, Wiener I (1984) Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J 52: 106–111PubMedCrossRefGoogle Scholar
  5. 5.
    Packer M, Medina N, Yushak M (1984) Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. JACC 4: 890–901PubMedGoogle Scholar
  6. 6.
    Packer M (1985) Vasodilator therapy for primary pulmonary hypertension. Ann Int Med 103: 258–270PubMedGoogle Scholar
  7. 7.
    Sesto M, Invancic R, Custovic F (1983) Die Wirkung von Gallopamil auf die Hämodynamik bei Patienten mit KHK. In: Kaltenbach M, Hopf R (eds.) Gallopamil. Pharmakologisches und klinisches Wirkungsprofil eines Kalziumantagonisten. Springer, Berlin Heidelberg New York Tokyo, pp. 97–100.Google Scholar
  8. 8.
    Simon R (1984) Kalziumantagonisten: Wirkung auf periphere und koronare Hämodynamik. Z Kardiol 73, Suppl 2:79–88PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1989

Authors and Affiliations

  • P. Richter
    • 1
    • 2
  • M. Stauch
    • 1
    • 2
  1. 1.Department of Cardiovascular and Respiratory MedicineUniversity of UlmGermany
  2. 2.Sektion Kardiologie, Angiologie und Pulmologie Zentrum für Innere MedizinKlinikum der Universität UlmUlmWest Germany

Personalised recommendations